Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.66 USD | +0.71% | +2.72% | -4.90% |
Apr. 08 | ElectroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness | CI |
Mar. 13 | ElectroCore, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.90% | 33.73M | D+ | ||
+72.39% | 12.33B | B- | ||
-18.22% | 7.86B | C+ | ||
+16.84% | 7.11B | C- | ||
+3.48% | 5.77B | B | ||
+8.16% | 5.1B | D+ | ||
+19.97% | 4.29B | - | ||
-20.59% | 3.92B | B- | ||
-42.79% | 2.2B | C | ||
+0.87% | 1.92B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ECOR Stock
- Ratings electroCore, Inc.